Moderna

$XTALPI(02228.HK) On the plane, reading some materials on Moderna, I suddenly feel that maybe Crownpeak's decision to abandon its own pipeline and focus solely on being a platform could be a mistake. This might be a potential concern and point of reflection for the market in its pricing. After all, the business model of a platform approach always lacks certainty. However, interestingly, Crownpeak's role in driving pipeline progress within the ecosystem is positive.

It really puts me in a dilemma.

I’m not sure the surge in Moderna’s price will last given the previous experience of it giving back the gains very quickly. Buy on rumour and sell on news?

An interesting opinion I read the other day when someone said the typical Singaporean "safe investment" of chasing STI etf/ 3 local banks could be riskier than one would think it is. The heavy concentration in the banking sector and lack of diversification could prove risky from time to time as the financial sector is tightly linked to interest rate cycles, property markets and non wealth products. On the flipside, the blue chip companies have been proven over time to generate decent and stable returns (including consistent dividend payouts).

In short as said many times, trust your thesis love your leader, all things will comes into flow cos the leader cannot lose more than us. We are nothing compared to their own reputation. Swings is inevitable as this is a stock market. Bottom line love your leader !💪🇺🇸🤺🎢⛳️😎❤️

$Moderna(MRNA.US) although momentum is cooling off, the setup is still in tact and holding the mighty pink line.

$Moderna(MRNA.US)

1️⃣ Exploded high after Moderna and Merck announced positive Ph3 result for their personalised mRNA melanoma cancer therapy, the first mRNA cancer treatment to achieve such a milestone. The news triggered a major short squeeze and a sharp re rating of Moderna’s future prospects.

2️⃣ I added a position cause the market narrative changed from a declining COVID company to a potential cancer treatment platform. One successful Ph3 trial can reshape future revenues expectations.

3️⃣ AI stocks depend mainly on earnings, adoption and valuation. MRNA depends on clinical, regulatory and pipeline milestones. In 2 months, I would gauge MRNA by follow through data and institutional support, not hype. 💊🩻🩺

$Moderna(MRNA.US)

Moderna: Cancer Vaccine Changes the Game — But Don’t Chase the Spike

Moderna’s 177% single-day surge followed a major breakthrough: its personalised mRNA cancer vaccine, intismeran, met the primary endpoint in a Phase 3 melanoma trial with Merck’s Keytruda, reducing recurrence and cancer spread. (Business Insider⁠)

This is a genuine validation of personalised cancer vaccines. Earlier Phase 2b data showed a 49% reduction in recurrence/death risk and 59% reduction in distant metastasis/death over five years. (Merck.com⁠) However, detailed Phase 3 data and overall-survival results are still pending, so regulatory and commercial risks remain.

Fundamentally, Moderna remains loss-making: Q2 revenue was only $100m, with a $800m net loss, although year-end cash guidance improved to $4.7–5.2bn. (Moderna Investors⁠) Valuation has consequently rerated dramatically, while technically the stock is severely extended after the historic gap-up.

Outlook: HOLD — not Buy at this level. Accumulate only after consolidation or a substantial retracement.

Option writers: favour 30–60 DTE cash-secured puts, targeting 15–25 delta, rather than chasing covered calls immediately. For bearish traders, consider 30–45 DTE calls around 15–20 delta, but only with defined risk.

Not financial advice.

$Pfizer(PFE.US)

Context: Seeing Moderna leverage OpenAI and generative AI to accelerate its mRNA clinical pipeline made me re-evaluate legacy pharma. Pfizer has been heavily integrating AI through platforms like “Charlie” and partnerships with CytoReason to compress drug discovery timelines and cut R&D overhead. With Pfizer’s oncology push and compressed valuation post-COVID, AI efficiency could significantly improve long-term trial success rates and margins.

My trade: Opened a position. The risk-to-reward ratio looks attractive given the low valuation multiples, solid dividend yield, and underappreciated AI-driven R&D pipeline optimization compared to pure biotech peers.

Takeaway: Next time, I will scale in using smaller dollar-cost averaging tranches rather than opening a full starter position all at once to navigate sector volatility.

@Captain's Watch